Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas

Haematologica

Volumn 84, Issue 10, 1999, Pages 911-916

  López, Rosario ^a   Martino, Rodrigo ^a   Brunet, Salut ^a   Sureda, Anna ^a   Domingo Albós, Andreu ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Follicular lymphomas; IAPVP 16; Salvage chemotherapy

Indexed keywords

CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHYLPREDNISOLONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; NAUSEA; NEUROTOXICITY; SOMNOLENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0344199384     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984; 311:1471-5.
2. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986; 4:1470-80.
3. Johnson PWM, Rohatiner AZS, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13:140-7.
4. Cabanillas F, Hagemeister FB, Bodey GP et al. IMVP-16, an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60:693-7.
5. Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5:407-12.
6. Rodriguez-Monge, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. Hematol Oncol Clin N Am 1997; 11:937-47.
7. Rodriguez FC, Cabanillas F, Velasquez WS, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13:1734-41.
8. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14:1262-8.
9. Zinzani PL, Bendandi M, Tura S. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 1995; 55:262-6.
10. Pigaditou A, Rohatiner AJS, Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20:24-7.
11. Hochster HS, Kyungmann Kim, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Croup Study. J Clin Oncol 1992; 10:28-32.
12. Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:2139-44.
13. Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:788-92.
14. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10:371-7.
15. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33.
16. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.
17. López R, Martino R, Sureda A, et al. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience. Haematologica 1999; 84: 350-5.
18. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81:3449-57.
19. López-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91:2955-60.
20. 2) after salvage chemotherapy for lymphoma. Bone Marrow Transplant 1997; 20:855-8.
21. Santamaría A, Martino R, Martínez C. Factors predicting an adequate mobilization of peripheral blood stem cell following IAPVP-16 + G-CSF in patients with lymphoid malignancies [abstract]. Blood 1998; 92 (Suppl.1):306b.
22. Freedman AS, Gribben JG, Nadler LM. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Leuk Lymphoma 1998; 28:219-30.
23. Muñoz L, Martino R, Subirà M, et al. Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampicin during short-duration neutropenia in patients with lymphoma. Leuk Lymphoma (in press).